GEN Stock Overview
Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Genomed Spólka Akcyjna Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł29.60 |
52 Week High | zł41.00 |
52 Week Low | zł29.40 |
Beta | 0.027 |
1 Month Change | 0.68% |
3 Month Change | -0.67% |
1 Year Change | -18.68% |
3 Year Change | -26.00% |
5 Year Change | 28.70% |
Change since IPO | 5.71% |
Recent News & Updates
Recent updates
Shareholder Returns
GEN | PL Biotechs | PL Market | |
---|---|---|---|
7D | 0% | 0.1% | 1.0% |
1Y | -18.7% | -19.0% | 33.5% |
Return vs Industry: GEN underperformed the Polish Biotechs industry which returned -17.6% over the past year.
Return vs Market: GEN underperformed the Polish Market which returned 35.3% over the past year.
Price Volatility
GEN volatility | |
---|---|
GEN Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 4.8% |
Market Average Movement | 5.0% |
10% most volatile stocks in PL Market | 9.2% |
10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: GEN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GEN's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 45 | Anna Boguszewska-Chachulska | https://www.genomed.pl |
Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers the analysis of mutations responsible for congenital diseases in approximately 6,500 genes; and next-generation sequencing technology.
Genomed Spólka Akcyjna Fundamentals Summary
GEN fundamental statistics | |
---|---|
Market cap | zł39.11m |
Earnings (TTM) | zł991.51k |
Revenue (TTM) | zł22.48m |
39.4x
P/E Ratio1.7x
P/S RatioIs GEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GEN income statement (TTM) | |
---|---|
Revenue | zł22.48m |
Cost of Revenue | zł8.35m |
Gross Profit | zł14.12m |
Other Expenses | zł13.13m |
Earnings | zł991.51k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | 0.75 |
Gross Margin | 62.83% |
Net Profit Margin | 4.41% |
Debt/Equity Ratio | 0% |
How did GEN perform over the long term?
See historical performance and comparison